OncoMatch/Clinical Trials/NCT06560528
Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
Is NCT06560528 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for gastric cancer.
Treatment: combination with Disitamab Vedotin and with Tislelizumab and Capecitabine — The efficacy and safety of combination with Disitamab Vedotin and with Tislelizumab and Capecitabine for perioperative treatment of locally advanced gastric cancer with HER2 overexpression.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression (ihc 3+ or 2+)
Disease stage
Required: Stage Ⅱ, Ⅲ (AJCC 8th)
Clinical stage Ⅱ, Ⅲ (cT2-4a ,N+ or -, M0, AJCC 8th)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: anti-tumor systemic therapy
Exception: adjuvant or neoadjuvant therapy allowed if completed >= 4 weeks before study and all adverse events recovered to ≤ CTCAE level 1 (except hair loss and pigmentation)
Patients who have received other anti-tumor systemic therapy in the past (including traditional Chinese medicine with anti-tumor indications), and have been less than 4 weeks from the completion of treatment to the administration of this study, or the adverse events caused by previous treatment have not recovered to ≤ CTCAE level 1 (except hair loss and pigmentation)
Lab requirements
Blood counts
Major organs are functioning normally
Kidney function
Major organs are functioning normally
Liver function
Major organs are functioning normally
Major organs are functioning normally
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06560528 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage Ⅱ or Ⅲ is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify